TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last?

TG Therapeutics TGTX shares ended the last trading session 7.5% higher at $29.74. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.6% loss over the past four weeks.This jump in share price came after management reported preliminary sales of its sole-marketed drug Briumvi for the full year 2024. TGTX claims to have added $310 million from the drug’s sales in 2024, surpassing management’s prior expectation of $300-$305 million. Management also provided an encouraging outlook for 2025, expecting to record $540 million in total revenues.This biopharmaceutical company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents a year-over-year change of +177.8%. Revenues are expected to be $96.61 million, up 119.7% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For TG Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TGTX going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>TG Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Puma Biotech PBYI, finished the last trading session 0.3% higher at $3.09. PBYI has returned 2.7% over the past month.Puma Biotech's consensus EPS estimate for the upcoming report has changed +50% over the past month to $0.14. Compared to the company's year-ago EPS, this represents a change of -54.8%. Puma Biotech currently boasts a Zacks Rank of #3 (Hold).Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks